Information Provided By:
Fly News Breaks for January 3, 2018
CMD
Jan 3, 2018 | 06:27 EDT
Raymond James analyst Lawrence Keusch upgraded Cantel Medical to Outperform from Market Perform and established a $115 price target. Keusch contents Cantel is a unique mid-cap growth story with a strong market position and earnings growth in the 13%-15% range. He expects robust earnings growth of 7%-9%, further accretive M&A, and income statement leverage beginning in FY19. The analyst has increased confidence Cantel can maintain its leadership position in the automated endoscope reprocessor market, which is a key growth driver due to competitor limitations.
News For CMD From the Last 2 Days
There are no results for your query CMD